Anti-Human VEGFR2/CD309 Rabbit Recombinant Antibody, PBS Only

VEGFR2/CD309 Recombinant Antibody for FC

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

FC

Conjugate

Unconjugated

CloneNo.

230238B11

Cat no : 98009-1-PBS

Synonyms

KDR, VEGFR2, VEGFR2/KDR, Protein-tyrosine kinase receptor flk-1, FLK-1


☆大好評トライアルサイズ ¥20,000~! >>> 一次抗体特別価格キャンペーン開催中!


Tested Applications

Positive FC detected inHUVEC cells

Recommended dilution

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Product Information

98009-1-PBS targets VEGFR2/CD309 in FC applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Rabbit / IgG
Class Recombinant
Type Antibody
Immunogen Recombinant protein 相同性解析による交差性が予測される生物種
Full Name kinase insert domain receptor (a type III receptor tyrosine kinase)
Calculated molecular weight152kd
GenBank accession numberNM_002253
Gene symbol KDR
Gene ID (NCBI) 3791
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS only
Storage ConditionsStore at -80°C. Stable for one year after shipment.

Background Information

VEGFR2, also named as CD309, KDR and FLK1, is a receptor for VEGF or VEGFC. VEGFR2 which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGFR2 functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.

Protocols

Product Specific Protocols
FC protocol for VEGFR2/CD309 antibody 98009-1-PBSDownload protocol
Standard Protocols
Click here to view our Standard Protocols